Manuscript CRC-Aspirin

Manuscript CRC-Aspirin

<p> Use of Aspirin postdiagnosis improves survival for colon cancer patients </p><p>Supplement 1: Aspirin and type of non-aspirin NSAIDs prescribed </p><p>Name Code Doses Users prediagnosis Users postdiagnosis</p><p> n=2086 n=1219 Acetylsalicyzuur B01AC06 30 mg/day (5.0%) 741 1095</p><p>80 mg/day (95%) Acetylsalicylzuur NO2BA01 300-500 mg 7 8 Indometacine M01AB01 25-100 mg 71 70 Sulindac M01AB02 100-200 mg 5 15 Diclofenac M01AB05 25-100 mg 1004 1628 Biofenac M01AB16 100 mg 14 6 Arthrotec M01AB55 50-75 mg 215 363 Piroxicam M01AC01 10-20 mg 71 24 Tilcotil M01AC02 20 mg 1 0 Meloxicam M01AC06 7.5-15 mg 247 338 Ibuprofen M01AE01 200-600 mg 627 633 Naproxen M01AE02 250-500 mg 675 947 Ketoprofen M01AE03 100-200 mg 12 5 Froben M01AE09 50-200 mg 4 4 Surgam M01AE11 200-300 mg 8 5 Seractil M01AE14 200-400 mg 8 5 Celebrex M01AH01 100-200 mg 84 229 Vioxx M01AH02 12.5-25 mg 216 259 Bextra M01AH03 20-40 mg 4 11 Arcoxia M01AH05 30-120 mg 39 132 Nabumeton M01AX01 500 mg 81 33 Prolixan M01AX04 300-600 mg 8 0 Carbasal NO2BA15 600 mg 99 58 ACCod NO2BA51 400/50/9.6 mg 24 6 Novalgin NO2BB02 500 mg 0 2</p><p>The total number adds up to more than 100% as some patients had 2 or more NSAIDs prescribed. </p><p>1</p>

View Full Text

Details

  • File Type
    pdf
  • Upload Time
    -
  • Content Languages
    English
  • Upload User
    Anonymous/Not logged-in
  • File Pages
    1 Page
  • File Size
    -

Download

Channel Download Status
Express Download Enable

Copyright

We respect the copyrights and intellectual property rights of all users. All uploaded documents are either original works of the uploader or authorized works of the rightful owners.

  • Not to be reproduced or distributed without explicit permission.
  • Not used for commercial purposes outside of approved use cases.
  • Not used to infringe on the rights of the original creators.
  • If you believe any content infringes your copyright, please contact us immediately.

Support

For help with questions, suggestions, or problems, please contact us